TWO · 7729.TWO
Steminent Biotherapeutics Inc.
NT$177.00+NT$2.50 (+1.43%)
Steminent Biotherapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.25% below the high.
Loading market information…
TWO · 6986.TWO · TWD
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:21 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
HeXun Biosciences Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 39.53% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
HeXun Biosciences Co., Ltd.’s next earnings report is currently expected on Mar 12, 2027, with estimated earnings per share of NT$0.80. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow HeXun Biosciences Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
HeXun Biosciences Co., Ltd., a Taiwanese enterprise, focuses on the research, development, and application of stem cell technologies and treatments. The company also offers a comprehensive suite of related services, including contract development and manufacturing for various cell types and their derivatives, outsourced production capabilities, quality control inspections, expert consulting, laboratory information management system (LIMS) implementation, and sterile (aseptic) filling solutions. Founded in 2019, its operations are headquartered in Taoyuan City, Taiwan.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:32 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$177.00+NT$2.50 (+1.43%)
Steminent Biotherapeutics Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.25% below the high.
NT$26.95+NT$0.55 (+2.08%)
Intech Biopharm Corporation’s quoted price sits in the lower half of its reported 52-week range, 36.56% below the high.
NT$29.00-NT$0.75 (-2.52%)
Apex Biotechnology Corp.’s quoted price sits in the lower half of its reported 52-week range, 15.45% below the high.
NT$26.40-NT$0.40 (-1.49%)
Taiwan Bio Therapeutics Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 19.76% below the high.
NT$21.30-NT$0.15 (-0.7%)
GlycoNex Incorporation’s quoted price sits in the lower half of its reported 52-week range, 29.0% below the high.
NT$20.80-NT$0.30 (-1.42%)
Gwo Xi Stem Cell Applied Technology Co. , Ltd’s quoted price sits in the lower half of its reported 52-week range, 28.03% below the high.
NT$54.70+NT$0.40 (+0.74%)
Dynamic Medical Technologies Inc.’s quoted price sits in the lower half of its reported 52-week range, 19.79% below the high.
NT$26.55-NT$0.05 (-0.19%)
G&E Herbal Biotechnology Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 42.88% below the high.
